To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Diabetic neuropathy (DN) is one of the main microvascular complications of both type 1 and
type 2 diabetes mellitus. Sometimes, this could already be present at the time of diagnosis …

Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition associated
with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Since systemic metabolic …

Type 2 diabetes mellitus (T2DM) is a worldwide major health burden and heart failure (HF)
is the most common cardiovascular (CV) complication in affected patients. Therefore …

In recent years, the incidence of non-viral hepatocellular carcinoma (HCC) has increased
dramatically, which is probably related to the increased prevalence of metabolic syndrome …

Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …

Metformin, a well‐known AMPK agonist, has been widely used as the first‐line drug for
treating type 2 diabetes. There had been a significant concern regarding the use of …

The prevalence of type 2 diabetes (T2D) has reached a pandemic scale. Systemic chronic
inflammation dominates the diabetes pathophysiology and has been implicated as a causal …

Cardiovascular (CV) disease and heart failure (HF) are the leading cause of mortality in type
2 diabetes (T2DM), a metabolic disease which represents a fast-growing health challenge …

The present study aims to compare the oxidative stress biomarkers, pro-inflammatory
cytokines, and histological changes induced by three cardiovascular risk factors, namely …